Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Other Non-Current Liabilities (2016 - 2025)

Zevra Therapeutics' Other Non-Current Liabilities history spans 9 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 90.38% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, down 90.38%, while the annual FY2025 figure was $1.7 million, 90.38% down from the prior year.
  • Other Non-Current Liabilities reached $1.7 million in Q4 2025 per ZVRA's latest filing, down from $17.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $17.8 million in Q4 2024 to a low of $14000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $4.9 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: soared 29732.0% in 2023, then tumbled 90.38% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $31000.0 in 2021, then fell by 19.35% to $25000.0 in 2022, then skyrocketed by 29732.0% to $7.5 million in 2023, then skyrocketed by 138.72% to $17.8 million in 2024, then crashed by 90.38% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Other Non-Current Liabilities are $1.7 million (Q4 2025), $17.5 million (Q3 2025), and $17.5 million (Q2 2025).